MRNA Gets Positive CHMP Opinion for Updated COVID-19 Jab
https://www.zacks.com/stock/news/2332825/mrna-gets-positive-chmp-opinion-for-updated-covid-19-jab?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2332825
Sep 06, 2024 - The Committee for Medicinal Products for Human Use recommends marketing authorization for Moderna's updated mRNA COVID-19 jab, Spikevax.
0
Pharma Stock Roundup: EU Nod for Expanded Use of MRK's Keytruda & More
https://www.zacks.com/stock/news/2332784/pharma-stock-roundup-eu-nod-for-expanded-use-of-mrk-s-keytruda-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2332784
Sep 06, 2024 - European Commission approves expanded use of Merck's Keytruda in bladder cancer. Sanofi & Lilly announce data from phase III studies on pipeline candidates.
0
Merck's Keytruda & Padcev Combo Gets EU Nod for Urothelial Carcinoma
https://www.zacks.com/stock/news/2331488/merck-s-keytruda-padcev-combo-gets-eu-nod-for-urothelial-carcinoma?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2331488
Sep 04, 2024 - MRK's Keytruda gets approval in combination with Astellas and Pfizer's Padcev for treating first-line advanced urothelial carcinoma.
0
Novavax Stock Up 9% on FDA Nod for Updated COVID-19 Vaccine
https://www.zacks.com/stock/news/2330525/novavax-stock-up-9-on-fda-nod-for-updated-covid-19-vaccine?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2330525
Sep 02, 2024 - The FDA authorization for NVAX's updated COVID-19 vaccine makes it the only non-mRNA vaccine option in the country.
0
Pharma Stock Roundup: LLY Offers Cheap Zepbound, EU Okays Some Drugs
https://www.zacks.com/stock/news/2329707/pharma-stock-roundup-lly-offers-cheap-zepbound-eu-okays-some-drugs?cid=CS-ZC-FT-analyst_blog|stock_roundup-2329707
Aug 30, 2024 - LLY launches a discounted version of Zepbound. European Commission approves JNJ's Balversa, MRK's Winrevair and RHHBY's PiaSky.
0
GSK's RSV Vaccine Arexvy Gets EU Nod for Adults Aged 50-59 Years
https://www.zacks.com/stock/news/2329179/gsk-s-rsv-vaccine-arexvy-gets-eu-nod-for-adults-aged-50-59-years?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2329179
Aug 29, 2024 - The European Commission approves GSK's RSV vaccine, Arexvy, for use in adults aged 50-59 years with increased risk of the disease.
0
Pfizer Follows Lilly's Example, Unveils DTC Service for Selling Drugs
https://www.zacks.com/stock/news/2328497/pfizer-follows-lilly-s-example-unveils-dtc-service-for-selling-drugs?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2328497
Aug 28, 2024 - PFE's digital pharmacy aims to provide patients easy access to its medicines for COVID-19, migraine and other conditions.
0
Pharma Stock Roundup: FDA Nod to PFE, MRNA New COVID Jabs & More
https://www.zacks.com/stock/news/2326355/pharma-stock-roundup-fda-nod-to-pfe-mrna-new-covid-jabs-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2326355
Aug 23, 2024 - LLY's phase III study shows that tirzepatide reduces the risk of developing type II diabetes. FDA approves PFE and MRNA's updated COVID-19 vaccine.
0
Top Analyst Reports for Apple, NVIDIA & Coca-Cola
https://www.zacks.com/commentary/2324434/top-analyst-reports-for-apple-nvidia-coca-cola?cid=CS-ZC-FT-research_daily-2324434
Aug 20, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), NVIDIA Corporation (NVDA) and The Coca-Cola Company (KO), as well as two micro-cap stocks Star Group, L.P. (SGU) and Aware, Inc. (AWRE).
0
How Should You Play Pfizer (PFE) After COVID-Flu Shot Setback?
https://www.zacks.com/stock/news/2324368/how-should-you-play-pfizer-pfe-after-covid-flu-shot-setback?cid=CS-ZC-FT-analyst_blog|most_popular_stocks-2324368
Aug 20, 2024 - After Pfizer's (PFE) better-than-expected second-quarter results and the bullish outlook for the year, investors who own Pfizer's stock may consider staying invested.
0